NCT04468984: Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis
- State
- Under way
- Phase
- Phase 3
- People
- 330 planned
- Started
- 31 Aug 2020
- Primary completion
- 29 Jan 2025
- Arms
- Arm A: Navitoclax + Ruxolitinib
- Results
- None posted
- 13 Jul 2020: Trial registered
- 31 Aug 2020: Trial started